Exelixis: new recommendations for Cabometyx tablets in national guidelines

Exelixis announced that the National Comprehensive Cancer Network, or NCCN, updated its Clinical Practice Guidelines to include new recommendations for Cabometyx tablets. With the updates, Cabometyx is recommended by the NCCN for the treatment of advanced renal cell carcinoma, or RCC, regardless of patient risk status. Key Cabometyx-related highlights from the updated NCCN Clinical Practice Guidelines for Kidney Cancer include: Cabometyx is the only preferred tyrosine kinase inhibitor treatment option for first-line patients in the poor- and intermediate-risk groups; Cabometyx is a recommended first-line treatment option for favorable-risk patients; Cabometyx is the only preferred TKI treatment option for previously treated patients.
https://thefly.com/landingPageNews.php?id=2787273